Our results suggest that Arkadia enhances TGF-β signaling by inducing degradation of SnoN, which is a negative regulator of TGF-β signaling that acts in different ways, and MG132 may have a positive function in the treatment of diabetic nephropathy by inhibiting the disorders involving SnoN ubiquitination. This evidence concerns the gene TGFB1 and diabetic kidney disease.